Occupational Therapist Assists Patients in Returning to Functional Independence

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

Dorinda Rodriguez, DrOT, OTR, CHT, has served as a helping hand for her patients in the Rio Grande Valley for the past 17 years. “My professional service gives me the opportunity to utilize the occupational therapy core values of altruism, equality, dignity, and prudence to make a meaningful contribution to a better community,” Dorinda Rodriguez said.

With hard work and perseverance, she successfully obtained a Bachelor of Science degree in Occupational Therapy from the University of Texas Health Science Center in San Antonio; she completed a Hand Therapy Fellowship Program through Texas Woman’s University and the Hand and Upper Extremity Institute of the Baylor College of Medicine. In 2001, Rodriguez became a certified hand therapist; and in 2016 she earned a Doctorate in Occupational Therapy from Rocky Mountain University of Health Professionals in Provo, Utah.

“My education has provided me with professional growth for developing knowledge and expertise for patient care in the specialty field of hand therapy to effectively treat patients with upper extremity related injuries,” she said.

- Advertisement -

She uses her years of experience in the treatment of upper extremity conditions to treats patients at her practice named RGV Hand Therapy Center in Edinburg. Dorinda’s approach is to provide a client-centered type of treatment in which the patient and the therapist mutually agree on the patient’s goals, so they can return to their day-to-day activities.

“We allow the patient to incorporate their own needs and goals into our treatment plans. That in itself, allows the patient to feel like they are accomplishing a goal that is very meaningful to them.”

Her capstone project, The Occupational Therapist’s Role in Hand Therapy: A Collaborative Approach to Health Care Success, utilizes evidence-based research to support an inter-professional course designed to educate future healthcare professionals. The course also includes clinically relevant and evidence-based therapeutic interventions intended to help improve the efficiency and effectiveness of the occupational therapist’s treatment approach.

“I would like to emphasize that one of the reasons that I continue to enjoy my profession is that I am able to assist clients in returning to functional independence after an injury or illness. This job allows me the satisfaction of seeing people return to the things they love to do!” Dorinda said.

- Advertisement -

For more information, call (956) 661-9490 to visit the RGV Hand Therapy Center at 5119 S. McColl Rd, Edinburg, Texas 78539. MDN

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.

Texas Oncology Expands Cancer Care With New McAllen West Clinic

Texas Oncology celebrated the grand opening of its McAllen West clinic Sept. 29, expanding cancer treatment, diagnostic, and research capabilities in the Rio Grande Valley as the organization continues its presence in the region, spanning more than 40 years.

Multicancer Blood Test Detects 17 Cancer Types in Large Prospective Study

A large prospective study published in Nature Medicine found that a blood test designed to detect multiple cancers identified cancer signals across 17 broad cancer types, such as ovarian, lung, breast and colorectal cancers, and many which do not have recommended screening tests.

Pancreatic Cancer Patients Gain Early Access to Experimental Drug Daraxonrasib Following Fast-Track FDA Decision

The U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.
- Advertisement -